Cosmos Health Expands U.S. Nutraceutical Portfolio with Oliv18 Launch
Event summary
- Cosmos Health launched Oliv18, a USDA and EU organic-certified olive polyphenol supplement, targeting cardiovascular and antioxidant markets.
- The product delivers 250 mg daily dose of hydroxytyrosol, meeting EFSA's 5 mg/day minimum for LDL oxidation protection.
- Oliv18 is positioned within the $33 billion global cardiovascular and antioxidant market projected by 2035.
- The launch expands Cosmos Health's 18 Series nutraceutical platform in the U.S.
The big picture
Cosmos Health's Oliv18 launch aligns with the growing consumer demand for evidence-backed natural health solutions. The product's science-driven formulation and premium positioning reflect broader industry trends toward preventive wellness and regulatory-compliant nutraceuticals. The cardiovascular and antioxidant markets, projected to exceed $33 billion globally by 2035, present significant growth opportunities for Cosmos Health's 18 Series platform.
What we're watching
- Market Penetration
- How Oliv18 will compete in the crowded U.S. cardiovascular and antioxidant supplement market.
- Regulatory Compliance
- Whether Cosmos Health can maintain its USDA and EU organic certifications while scaling production.
- Product Differentiation
- The pace at which competitors adopt similar science-driven formulations.
Related topics